

USSN: 08/349,489 Dkt. No.: PP00999.104

2300-0999

## **AMENDMENTS TO THE CLAIMS**

This listing of the claims replaces all prior listings and versions:

- 1. (currently amended): A method of inducing production of antibodies against a cancer antigen, comprising the step of administering a bispecific antibody to the a human patient, said bispecific antibody comprising a first binding site capable of recognizing and binding a first antigen wherein said first antigen is FcyRIII and further comprising a second binding site capable of recognizing and binding a second antigen, in an amount sufficient to induce production of antibodies to said second antigen in said patient, wherein said second antigen is a cancer antigen selected from the group consisting of c-erbB-2, HMW mucin, HMW mucin II, and p-glycoprotein and further wherein said second binding site comprises a binding site derived from a monoclonal antibody produced by a hybridoma selected from the group consisting of: HB11830, 452F2 (HB 10811), 741F8 (HB 10807), 759E3 (HB 10808), 454C11 (HB 8484). 387H9 (HB 10802), 113F1 (HB 8490), 317G5 (HB 8485, HB 8691), 34F2 (HB 11052), 650E2 (HB 10812), 35E6 (HB 11769), 266B2 (HB 8486), 106A10 (HB 10789), 260F9 (HB 8488 and HB 8662), 33F8 (HB 8697), 9C6 (HB 10785), 35E10 (HB 10796), 140A7 (HB 10798), 36H3 (HB11768), 788G6 (HB 8692), 200F9 (HB 10791), 697B3 (HB 10806), 120H7 (HB 10790), 203E2 (HB 10799), 254H9 (HB 10792), 245E7 (HB 8489), 2G3 (HB 8491), 369F10 (HB 8682). and 15D3 (HB 11342), 421E8 (HB 10793), 310B7 (HB 11752), 32A1 (HB 10795), 219F3 (HB 10801), 42E7 (HB 11751), and 388D4 (HB 10794).
- 2. (original): The method according to claim 1, wherein said first binding site is a binding site derived from the monoclonal antibody produced from the 3G8 hybridoma.
- 3. (original): The method according to claim 1, wherein said second antigen is present in the patient.
  - 4 to 7. (canceled).
- 8. (original): The method according to claim 1, wherein said bispecific antibody is produced by the hybrid hybridoma CRL 10197.
  - 9 to 15. (canceled).